Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle

Virology

Volumn 327, Issue 2, 2004, Pages 262-272

  Young, Kelly R ^a   Smith, James M ^b   Ross, Ted M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Antibody Systems Inc   (United States)

Author keywords

DNA vaccine; Human immunodeficiency virus type 1; VLP

Indexed keywords

CD4 ANTIGEN; DNA VACCINE; GENE PRODUCT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SUCROSE; VIRUS ANTIGEN; VIRUS ENZYME;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DENSITY; DRUG MECHANISM; GENE CONSTRUCT; GENE INSERTION; GENE SEQUENCE; GENETIC CODE; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICULATE MATTER; PLASMID; PRIMATE; PRIORITY JOURNAL; PROMOTER REGION; SOLUBILITY; SUPERNATANT; VACCINATION; VIRION;

AIDS VACCINES; ANIMALS; ANTIGENS, CD4; COS CELLS; HIV ANTIGENS; HIV-1; HUMANS; MUTATION; PLASMIDS; RETROVIRIDAE PROTEINS; TRANSFECTION; VACCINES, DNA; VIRAL REGULATORY PROTEINS; VIRION;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

EID: 4444255830     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2004.07.009     Document Type: Article

References (81)

1. L.G. Abrahamyan, R.M. Markosyan, J.P. Moore, F.S. Cohen, and G.B. Melikyan Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion J. Virol. 77 2003 5829 5836
2. E. Acheampong, M. Rosario-Otero, R. Dornburg, and R.J. Pomerantz Replication of lentiviruses Front. Biosci. 8 2003 s156 s174
3. W. Akahata, E. Ido, T. Shimada, K. Katsuyama, H. Yamamoto, H. Uesaka, M. Ui, T. Kuwata, H. Takahashi, and M. Hayami DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles Virology 275 2000 116 124
4. W. Akahata, E. Ido, H. Akiyama, H. Uesaka, Y. Enose, R. Horiuchi, T. Kuwata, T. Goto, H. Takahashi, and M. Hayami DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles J. Gen. Virol. 84 2003 2237 2244
5. W. Akahata, E. Ido, and M. Hayami Mutational analysis of two zinc-finger motifs in the nucleocapsid protein of simian immunodeficiency virus mac239 J. Gen. Virol. 84 2003 1641 1648
6. R.R. Amara, J.M. Smith, S.I. Staprans, D.C. Montefiori, F. Villinger, J.D. Altman, S.P. O'Neil, N.L. Kozyr, Y. Xu, L.S. Wyatt, P.L. Earl, J.G. Herndon, J.M. McNicholl, H.M. McClure, B. Moss, and H.L. Robinson Critical role for Env as well as Gagâ€"Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine J. Virol. 76 2002 6138 6146
7. R.R. Amara, F. Villinger, S.I. Staprans, J.D. Altman, D.C. Montefiori, N.L. Kozyr, Y. Xu, L.S. Wyatt, P.L. Earl, J.G. Herndon, H.M. McClure, B. Moss, and H.L. Robinson Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines J. Virol. 76 2002 7625 7631
8. J.L. Anderson, and T.J. Hope Recent Insights into HIV accessory proteins Curr. Infect. Dis. Rep. 5 2003 439 450
9. L.M. Babe, J. Rose, and C.S. Craik Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation Proc. Natl. Acad. Sci. U.S.A. 92 1995 10069 10073
10. J. Berger, J. Hauber, R. Hauber, R. Geiger, and B. Cullen Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells Gene 66 1988 1 10
11. J.F. Bower, X. Yang, J. Sodroski, and T.M. Ross Elicitation of improved neutralizing antibodies using DNA vaccines expressing soluble stabilized HIV-1 envelope glycoprotein trimers conjugated to C3d J. Virol. 78 2004 4710 4719
12. J. Boyer, M. Chattergoon, A. Shah, R. Ginsberg, R. MacGregor, and D. Weiner HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response Dev. Biol. Stand. 95 1998 147 153
13. S.L. Buge, H.L. Ma, R.R. Amara, L.S. Wyatt, P.L. Earl, F. Villinger, D.C. Montefiori, S.I. Staprans, Y. Xu, E. Carter, S.P. O'Neil, J.G. Herndon, E. Hill, B. Moss, H.L. Robinson, and J.M. McNicholl Gp120-alum boosting of a Gagâ€"Polâ€"Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge AIDS Res. Hum. Retroviruses 19 2003 891 900
14. L. Buonaguro, L. Racioppi, M.L. Tornesello, C. Arra, M.L. Visciano, B. Biryahwaho, S.D. Sempala, G. Giraldo, and F.M. Buonaguro Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A Antiviral Res. 54 2002 189 201
15. S.F. Chao, V.L. Chan, P. Juranka, A.H. Kaplan, R. Swanstrom, and C.A. Hutchison III Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1 Nucleic Acids Res. 23 1995 803 810
16. J.M. Crawford, P.L. Earl, B. Moss, K.A. Reimann, M.S. Wyand, K.H. Manson, M. Bilska, J.T. Zhou, C.D. Pauza, P.W. Parren, D.R. Burton, J.G. Sodroski, N.L. Letvin, and D.C. Montefiori Characterization of primary isolate-like variants of simian-human immunodeficiency virus J. Virol. 73 1999 10199 10207
17. B.R. Cullen Nuclear mRNA export: insights from virology Trends Biochem. Sci. 28 2003 419 424
18. M. Dettenhofer, and X.F. Yu Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions J. Virol. 73 1999 1460 1467
19. M. Dong, P.F. Zhang, F. Grieder, J. Lee, G. Krishnamurthy, T. VanCott, C. Broder, V.R. Polonis, X.F. Yu, Y. Shao, D. Faix, P. Valente, and G.V. Quinnan Jr. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system J. Virol. 77 2003 3119 3130
20. J.J. Donnelly, J.B. Ulmer, and M.A. Liu DNA vaccines Dev. Biol. Stand. 95 1998 43 53
21. F. Dorner, and P.N. Barrett Vaccine technology: looking to the future Ann. Med. 31 1999 51 60
22. D. Ellenberger, B. Li, J. Smith, H. Yi, T. Folks, H. Robinson, and S. Butera Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms Virology 319 2004 118 130
23. A. Engelman, and R. Craigie Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro J. Virol. 66 1992 6361 6369
24. A. Engelman, G. Englund, J.M. Orenstein, M.A. Martin, and R. Craigie Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication J. Virol. 69 1995 2729 2736
25. T.M. Fletcher III, M.A. Soares, S. McPhearson, H. Hui, M. Wiskerchen, M.A. Muesing, G.M. Shaw, A.D. Leavitt, J.D. Boeke, and B.H. Hahn Complementation of integrase function in HIV-1 virions EMBO J. 16 1997 5123 5138
26. E.O. Freed HIV-1 replication Somatic Cell Mol. Genet. 26 2001 13 33
27. T.D. Green, D.C. Montefiori, and T.M. Ross Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d J. Virol. 77 2003 2046 2055
28. N. Haigwood, C. Pierce, M. Robertson, A. Watson, D. Montefiori, M. Rabin, J. Lynch, L. Kuller, J. Thompson, W. Morton, R. Benvenister, S. Hu, P. Greenberg, and S. Mossman Protection from pathogenic SIV challenge using multigenic DNA vaccines Immunol. Lett. 66 1999 183 188
29. J. Hammonds, X. Chen, L. Ding, T. Fouts, A. De Vico, J. zur Megede, S. Barnett, and P. Spearman Gp120 stability on HIV-1 virions and Gagâ€"Env pseudovirions is enhanced by an uncleaved Gag core Virology 314 2003 636 649
30. G.A. Hardy, N. Imami, and F.M. Gotch Improving HIV-specific immune responses in HIV-infected patients J. HIV Ther. 7 2002 40 45
31. T.K. Hart, R. Kirsh, H. Ellens, R.W. Sweet, D.M. Lambert, J.S.R. Petteway, J. Leary, and P.J. Bugelski Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120 Proc. Natl. Acad. Sci. U.S.A. 88 1991 2189 2193
32. R.S. Hogg, B. Yip, C. Kully, K.J. Craib, M.V. O'Shaughnessy, M.T. Schechter, and J.S. Montaner Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens CMAJ 160 1999 659 665
33. M. Huang, J.M. Orenstein, M.A. Martin, and E.O. Freed p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease J. Virol. 69 1995 6810 6818
34. Y. Huang, W.P. Kong, and G.J. Nabel Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression J. Virol. 75 2001 4947 4951
35. A. Jaffy, E. Shepard, J. van Harmelen, C. Williamson, A.L. Williamson, and E.P. Rybicki Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice J. Gen. Virol. 85 2004 409 413
36. T. Jones Varivax (Merck and Co) Curr. Opin. Invest. Drugs 3 2002 54 57
37. S.M. Kang, and R.W. Compans Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus J. Virol. 77 2003 3615 3623
38. J. Kim, V. Ayyavoo, M. Bagarazzi, M. Chattergoon, J. Boyer, B. Wang, and D. Weiner Development of a multicomponent candidate vaccine for HIV-1 Vaccine 15 1997 879 883
39. J.J. Kim, J.S. Yang, K.H. Manson, and D.B. Weiner Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants Vaccine 19 2001 2496 2505
40. N.E. Kohl, E.A. Emini, W.A. Schleif, L.J. Davis, J.C. Heimbach, R.A. Dixon, E.M. Scolnick, and I.S. Sigal Active human immunodeficiency virus protease is required for viral infectivity Proc. Natl. Acad. Sci. U.S.A. 85 1988 4686 4690
41. A. Kumar, J.D. Lifson, P.S. Silverstein, F. Jia, D. Sheffer, Z. Li, and O. Narayan Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses Virology 274 2000 149 164
42. S.F. Le Grice, T. Naas, B. Wohlgensinger, and O. Schatz Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase EMBO J. 10 1991 3905 3911
43. K. Lindenburg, M.W. Langendam, J. Veenstra, F. Miedema, and R. Coutinho Long-term effects of therapeutic vaccination with rgp 120 AIDS 14 2000 203 204
44. M.A. Liu, T.M. Fu, J.J. Donnelly, M.J. Caulfield, and J.B. Ulmer DNA vaccines. Mechanisms for generation of immune responses Adv. Exp. Med. Biol. 452 1998 187 191
45. D.M. Lowe, V. Parmar, S.D. Kemp, and B.A. Larder Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase FEBS Lett. 282 1991 231 234
46. J.R. Mascola Defining the protective antibody response for HIV-1 Curr. Mol. Med. 3 2003 209 216
47. J.A. McKeating, A. McKnight, and J.P. Moore Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization J. Virol. 65 1991 852 860
48. R.E. Means, T. Greenough, and R.C. Desrosiers Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus J. Virol. 71 1997 7895 7902
49. L. Menendez-Arias, A. Mas, and E. Domingo Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase Viral Immunol. 11 1998 167 181
50. V. Mizrahi, R.L. Brooksbank, and N.C. Nkabinde Mutagenesis of the conserved aspartic acid 443, glutamic acid 478, asparagine 494, and aspartic acid 498 residues in the ribonuclease H domain of p66/p51 human immunodeficiency virus type I reverse transcriptase. Expression and biochemical analysis J. Biol. Chem. 269 1994 19245 19249
51. A. Mizuno, E. Ido, T. Goto, T. Kuwata, M. Nakai, and M. Hayami Mutational analysis of two zinc finger motifs in HIV type 1 nucleocapsid proteins: effects on proteolytic processing of Gag precursors and particle formation AIDS Res. Hum. Retroviruses 12 1996 793 800
52. J.P. Moore, L.C. Burkly, R.I. Connor, Y. Cao, R. Tizard, D.D. Ho, and R.A. Fisher Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4 AIDS Res. Hum. Retroviruses 9 1993 529 536
53. A.J. Mouland, J. Mercier, M. Luo, L. Bernier, L. DesGroseillers, and E.A. Cohen The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation J. Virol. 74 2000 5441 5451
54. K. Muthumani, M. Bagarazzi, D. Conway, D.S. Hwang, K. Manson, R. Ciccarelli, Z. Israel, D.C. Montefiori, K. Ugen, N. Miller, J. Kim, J. Boyer, and D.B. Weiner A Gagâ€"Pol/Envâ€"Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus macaques Vaccine 21 2003 629 637
55. C. Nilsson, B. Makitalo, R. Thorstensson, S. Norley, D. Binninger-Schinzel, M. Cranage, E. Rud, G. Biberfeld, and P. Putkonen Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm AIDS 12 1998 2261 2270
56. E. O'Neill, I. Martinez, F. Villinger, M. Rivera, S. Gascot, C. Colon, T. Arana, M. Sidhu, R. Stout, D.C. Montefiori, M. Martinez, A.A. Ansari, Z.R. Israel, and E. Kraiselburd Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration J. Med. Primatol. 31 2002 217 227
57. J. Park, and C.D. Morrow Overexpression of the gagâ€"pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production J. Virol. 65 1991 5111 5117
58. P. Pitisuttithum, S. Nitayaphan, P. Thongcharoen, C. Khamboonruang, J. Kim, M. de Souza, T. Chuenchitra, R.P. Garner, D. Thapinta, V. Polonis, S. Ratto-Kim, P. Chanbancherd, J. Chiu, D.L. Birx, A.M. Duliege, J.G. McNeil, and A.E. Brown Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults J. Infect. Dis. 188 2003 219 227
59. G.V. Quinnan Jr., P.F. Zhang, D.W. Fu, M. Dong, and H.J. Alter Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response AIDS Res. Hum. Retroviruses 15 1999 561 570
60. H.L. Robinson DNA vaccines for immunodeficiency viruses AIDS 11 Suppl. A 1997 S109 S119
61. H.L. Robinson, and T.M. Pertmer DNA vaccines for viral infections: basic studies and applications Adv. Virus Res. 55 2000 1 74
62. R.W. Sanders, L. Schiffner, A. Master, F. Kajumo, Y. Guo, T. Dragic, J.P. Moore, and J.M. Binley Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits J. Virol. 74 2000 5091 5100
63. R.W. Sanders, M. Vesanen, N. Schuelke, A. Master, L. Schiffner, R. Kalyanaraman, M. Paluch, B. Berkhout, P.J. Maddon, W.C. Olson, M. Lu, and J.P. Moore Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 J. Virol. 76 2002 8875 8889
64. N. Schulke, M.S. Vesanen, R.W. Sanders, P. Zhu, M. Lu, D.J. Anselma, A.R. Villa, P.W. Parren, J.M. Binley, K.H. Roux, P.J. Maddon, J.P. Moore, and W.C. Olson Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein J. Virol. 76 2002 7760 7776
65. A.J. Smith, N. Srinivasakumar, M.L. Hammarskjold, and D. Rekosh Requirements for incorporation of Pr160gagâ€"pol from human immunodeficiency virus type 1 into virus-like particles J. Virol. 67 1993 2266 2275
66. P. Spearman HIV vaccine development: lessons from the past and promise for the future Curr. HIV Res. 1 2003 101 120
67. L. Stevceva, and W. Strober Mucosal HIV vaccines: where are we now? Curr. HIV Res. 2 2004 1 10
68. S. Tang, T. Murakami, N. Cheng, A.C. Steven, E.O. Freed, and J.G. Levin Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase J. Virol. 77 2003 12592 15602
69. UNAIDS, www.unaids.org.
70. C.T. Wang, H.Y. Lai, and J.J. Li Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release J. Virol. 72 1998 7950 7959
71. S. Wang, P. Kozlowski, G. Schmelz, K. Manson, M. Wyand, R. Glickman, D. Montefiori, J. Lifson, R. Johnson, M. Neutra, and A. Aldovini Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions J. Virol. 74 2000 10514 10522
72. J. Warren Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates J. Med. Primatol. 31 2002 237 256
73. M.S. Wyand, K. Manson, D.C. Montefiori, J.D. Lifson, R.P. Johnson, and R.C. Desrosiers Protection by live, attenuated simian immunodeficiency virus against heterologous challenge J. Virol. 73 1999 8356 8363
74. S. Yamamoto, T.M. Folks, and W. Heneine Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems J. Virol. Methods 61 1996 135 143
75. X. Yang, L. Florin, M. Farzan, P. Kolchinsky, P.D. Kwong, J. Sodroski, and R. Wyatt Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution J. Virol. 74 2000 4746 4754
76. X. Yang, J. Lee, E.M. Mahony, P.D. Kwong, R. Wyatt, and J. Sodroski Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin J. Virol. 76 2002 4634 4642
77. Q. Yao, V. Vuong, M. Li, and R.W. Compans Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity Vaccine 20 2002 2537 2545
78. Q. Yao, Z. Bu, A. Vzorov, C. Yang, and R.W. Compans Virus-like particle and DNA-based candidate AIDS vaccines Vaccine 21 2003 638 643
79. K.R. Young, and T.M. Ross Particle-based vaccines for HIV-1 infection Curr. Drug Targets Infect. Disord. 3 2003 151 169
80. J.L. Yovandich, E.N. Chertova, B.P. Kane, T.D. Gagliardi, J.W. Bess, R.C. Sowder, L.E. Henderson, and R.J. Gorelick Alteration of zinc-binding residues of simian immunodeficiency virus p8(NC) results in subtle differences in gag processing and virion maturation associated with degradative loss of mutant NC J. Virol. 75 2001 115 124
81. P.F. Zhang, P. Bouma, E.J. Park, J.B. Margolick, J.E. Robinson, S. Zolla-Pazner, M.N. Flora, and G.V. Quinnan Jr. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response J. Virol. 76 2002 644 655